Regency Capital Management Inc. DE Sells 57,887 Shares of Aura Biosciences, Inc. (NASDAQ:AURA)

Regency Capital Management Inc. DE cut its stake in Aura Biosciences, Inc. (NASDAQ:AURA) by 8.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 609,424 shares of the company’s stock after selling 57,887 shares during the quarter. Aura Biosciences comprises about 2.7% of Regency Capital Management Inc. DE’s holdings, making the stock its 15th biggest holding. Regency Capital Management Inc. DE’s holdings in Aura Biosciences were worth $5,009,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Charles Schwab Investment Management Inc. lifted its stake in shares of Aura Biosciences by 2.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company’s stock valued at $1,233,000 after purchasing an additional 3,612 shares during the period. The Manufacturers Life Insurance Company raised its holdings in Aura Biosciences by 14.6% in the second quarter. The Manufacturers Life Insurance Company now owns 64,452 shares of the company’s stock worth $487,000 after purchasing an additional 8,194 shares in the last quarter. Renaissance Technologies LLC lifted its position in Aura Biosciences by 26.3% during the second quarter. Renaissance Technologies LLC now owns 72,100 shares of the company’s stock valued at $545,000 after buying an additional 15,000 shares during the period. American Century Companies Inc. bought a new stake in shares of Aura Biosciences during the 2nd quarter valued at $119,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Aura Biosciences in the 3rd quarter worth about $169,000. 96.75% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on AURA. BTIG Research lifted their price target on shares of Aura Biosciences from $21.00 to $24.00 and gave the company a “buy” rating in a research report on Friday, October 18th. HC Wainwright reiterated a “buy” rating and set a $22.00 target price on shares of Aura Biosciences in a report on Thursday, November 14th. Cowen restated a “buy” rating on shares of Aura Biosciences in a research note on Friday, October 18th. Finally, Scotiabank boosted their target price on Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a report on Friday, October 18th. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Aura Biosciences presently has an average rating of “Buy” and a consensus target price of $23.00.

Insider Transactions at Aura Biosciences

In other news, insider Los Pinos Elisabet De sold 15,955 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total transaction of $122,374.85. Following the sale, the insider now directly owns 304,692 shares in the company, valued at $2,336,987.64. This trade represents a 4.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Janet Jill Hopkins sold 11,822 shares of the business’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $9.36, for a total value of $110,653.92. Following the completion of the transaction, the insider now owns 151,693 shares in the company, valued at $1,419,846.48. The trade was a 7.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 38,531 shares of company stock worth $345,454 in the last three months. Corporate insiders own 5.40% of the company’s stock.

Aura Biosciences Stock Down 2.6 %

NASDAQ:AURA opened at $7.89 on Friday. Aura Biosciences, Inc. has a 52 week low of $6.63 and a 52 week high of $12.38. The stock has a market cap of $394.11 million, a price-to-earnings ratio of -4.56 and a beta of 0.30. The company’s 50 day moving average price is $8.38 and its 200-day moving average price is $8.92.

Aura Biosciences (NASDAQ:AURA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.02. As a group, sell-side analysts anticipate that Aura Biosciences, Inc. will post -1.67 earnings per share for the current year.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.